Leveraging Integrated RNA Sequencing to Decipher Adrenomedullin's Protective Mechanisms in Experimental

Subarna Palit1, Amrit Kumar Shrestha2, Shyam Thapa2

  • 1TUM School of Life Sciences Weihenstephan, Technical University of Munich, 85354 Freising, Germany.

Genes
|June 27, 2024
PubMed

Insights

Adrenomedullin (Adm) protects against experimental bronchopulmonary dysplasia (BPD) by reducing inflammation and altering immune cell populations. This suggests Adm is a potential therapeutic target for infants with BPD.

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Immunology

Background:

  • Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants with few treatments.
  • Adrenomedullin (Adm), a peptide hormone, shows protective effects in experimental BPD models.

Purpose of the Study:

  • To investigate the molecular and cellular mechanisms of Adrenomedullin (Adm) in bronchopulmonary dysplasia (BPD) pathogenesis.
  • To utilize a lipopolysaccharide (LPS)-induced mouse model for studying experimental BPD.

Main Methods:

  • Bulk and single-cell RNA sequencing of wild-type and Adm-haplodeficient mouse lungs exposed to LPS.
  • Computational integration with cell atlas data and analysis of human BPD patient data.

Main Results:

  • Adm deficiency and LPS exposure altered lung gene expression and cell types.
  • Adm-haplodeficient lungs showed increased inflammation, higher natural killer (NK) cell frequency, and reduced endothelial and type II pneumocyte cells.
  • Human BPD infant data confirmed elevated NK cell frequencies.

Conclusions:

  • Adrenomedullin plays a protective role in experimental BPD.
  • Adm influences BPD pathogenesis by modulating immune cell populations and lung cell frequencies.
  • Adm represents a potential therapeutic target for BPD, particularly in cases with an inflammatory phenotype.